Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma

doi:10.1097/MD.0000000000020443

	Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma
	Chen, Jing 1,2,3; Liu, Tongxin 1,2,3; Sun, Quanquan 1,2,3; Jin, Ting 1,2,3
刊名	MEDICINE
	2020-07-17
卷号	99
关键词	adjuvant chemotherapy concurrent chemoradiotherapy intensity-modulated radiotherapy prognosis stage II nasopharyngeal carcinoma
ISSN号	0025-7974
DOI	10.1097/MD.0000000000020443
通讯作者	Jin, Ting(jinjin_2019@163.com)
英文摘要	Background: Although common, the use of concurrent chemoradiotherapy with adjuvant chemotherapy for stage II nasopharyngeal carcinoma (NPC) is controversial due to its undefined clinical benefits. We, therefore, conducted a retrospective cohort study to investigate whether adjuvant chemotherapy confers survival gains to stage II NPC patients. Methods: In this study, we examined whether combining adjuvant chemotherapy (AC) and/or concurrent chemotherapy with radiotherapy (CCRT) improved survival in patients with stage II NPC. Three hundred thirty-five stage II NPC patients were retrospectively analyzed between June 2003 and June 2016 and received CCRT; some patient groups also received AC every 3 weeks for 2 to 3 cycles. Results: The median follow-up duration was 72 months for all patients (range, 26-151 months) and the estimated 5-year locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 95.1%, 97.8%, 93.5%, and 94.3%. At the last follow-up, there were no statistically significant differences among the CCRT and CCRT+AC groups in 5-year LRRFS (95.2% vs 94.9%,P = .599), DMFS (98.5% vs 92.4%,P = .152), PFS (93.8% vs 90.2%,P = .599), or OS (95.5% vs 93.9%,P = .682) rates. Conclusion: The analyses revealed that a combined regimen was not an independent prognostic factor for any survival outcome. However, patients who received CCRT plus AC experienced more acute adverse events than those who received CCRT alone. Thus, the addition of AC to CCRT did not improve survival outcomes, but was associated with higher incidences of acute treatment-associated toxicities than CCRT alone in patients with stage II NPC.
WOS关键词	RADIOTHERAPY ; PROGNOSIS ; CANCER
WOS研究方向	General & Internal Medicine
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000557513600004
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/44752]
专题	中国科学院合肥物质科学研究院
通讯作者	Jin, Ting
作者单位	1.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Zhejiang, Peoples R China 2.Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China 3.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Chen, Jing,Liu, Tongxin,Sun, Quanquan,et al. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma[J]. MEDICINE,2020,99.
APA	Chen, Jing,Liu, Tongxin,Sun, Quanquan,&Jin, Ting.(2020).Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.MEDICINE,99.
MLA	Chen, Jing,et al."Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma".MEDICINE 99(2020).